Cold Chain and Drug Storage: — Why Temperature Is Part of the Dose

A price that is substantially lower for the same molecule usually reflects one of three things: a shorter, less documented supply chain; storage conditions that were not continuously monitored; or a seller operating outside the regulated licensing system. Approved generics and biosimilars are required by CDSCO to meet the same quality standards as the originator — but that approval applies to drugs stored and handled according to the approved method. A drug that left the cold chain at any point is no longer the drug that was approved, regardless of what the label says.

No. This is the critical fact about cold-chain failure. A degraded drug is visually identical to an intact one. It will be the same colour, the same clarity, in the same container. Degradation happens at the molecular level. The only reliable evidence is the temperature log that should accompany every vial from the point of manufacture. Visual inspection is done at the pharmacy as a basic check, but it cannot detect temperature-related degradation.

A cold-chain breach does not mean the drug is automatically destroyed, but it does mean its integrity cannot be confirmed without further testing — testing that is not practically available at the point of use. The correct response to a documented breach is to quarantine the affected batch and contact the manufacturer or supplier. This is standard practice at licensed oncology pharmacies. A drug whose cold chain cannot be verified should not be used, because neither under-treatment nor unknown breakdown products can be ruled out.

Yes. CDSCO approval for a generic or biosimilar requires the same storage and handling conditions as the originator drug. The active molecule is the same, and so are its physical requirements. Regulatory equivalence at the point of approval does not extend to a drug that has subsequently been handled outside the approved storage conditions. An approved biosimilar sourced through an unverified supply chain carries exactly the same risks as any other drug with an unknown storage history.

Licensed oncology pharmacies are required by CDSCO and State Drug Authorities to maintain storage conditions specified by the manufacturer and to keep records of temperature monitoring. Drugs arrive with a certificate of analysis and batch documentation. Temperature loggers in transport vehicles and pharmacy cold rooms provide a continuous record. Pharmacists perform visual inspection at receipt and before dispensing. These checks create a chain of documented evidence that does not exist for drugs sourced outside this system.

This is a question for your oncologist, not a decision to make independently. Some treatment centres do ask families to source drugs — this is a practical reality in parts of India — and in those cases your team should specify where from and what to verify. What cannot be confirmed is a drug sourced from an unregulated online seller or unverified outlet, where no temperature log exists and no licensed pharmacist has prepared the dose. If you are being asked to bring a drug from outside, name the source to your oncologist and ask them to confirm it meets the storage and handling requirements for your treatment.